Prefer Cipla, Aurobindo Pharma: Gaurang Shah

Gaurang Shah of Geojit Financial Services told CNBC-TV18, "No specific coverage on Marksans Pharma, but from a long-term point of view my sense is that you are better off with names which have a proven track record like Aurobindo Pharma or Cipla. If I am not mistaken 2012-2013 this stock was a single digit stock and then we saw significant rally and then it has cooled off again. Lot of retail investors have got attracted to this particular stock. So, from a long-term point of view my sense is that Aurobindo Pharma or Cipla would be a better investment idea."

Cipla ended at Rs 592, down Rs 1.25, or 0.21 percent on the BSE.